Evidence map›Paper›PMID 26878134›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2016

Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma.

Naoki Wada, Jun-Ichiro Ikeda, Satoshi Nojima, Shin-Ichiro Tahara, Kenji Ohshima, Daisuke Okuzaki, Eiichi Morii

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Naoki WadaDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Jun-Ichiro IkedaDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Satoshi NojimaDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Shin-Ichiro TaharaDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Kenji OhshimaDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Daisuke OkuzakiDNA Chip Development Center, RIMD, Osaka University, Suita, Osaka, Japan.
Eiichi MoriiDepartment of Pathology (C3), Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
The University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer cells with tumorigenic potential are limited to a small subpopulation known as cancer-initiating cells (CICs). Recently we investigated a candidate of CICs of lymphoplasmacytic lymphoma (LPL), which is positive for both B-cell marker CD20 and plasma-cell marker CD138. We reported that the subpopulation of CD20(-) CD138(-) phenotype, in which both markers were negative was a candidate of CICs in LPL using LPL cell line, MWCL-1. CICs are known to be plastic under stressed condition, in which non-CICs are changed to CICs. In the present study, we investigated the plasticity of CICs of LPL, and found that hypoxia induced the conversion of CD20(+) CD138(-) to CD20(-) CD138(-) phenotype. We then searched for markers preferentially expressed in CD20(-) CD138(-) subpopulation, and the chemokine receptor CXCR7 was isolated. When cultured with CXCL12, a ligand of CXCR7, the number of CD20(-) CD138(-) cells increased in a time- and dose-dependent manner. In addition, hypoxia enhanced the expression level of CXCL12 in MWCL-1. In clinical samples of LPL, a few tumor cells expressed CXCR7, in which CD20 expression was not detected. These results indicated that hypoxia and CXCL12-CXCR7 axis appeared to be advantageous microenvironments to CD20(-) CD138(-) cells.

Indexed as

AgedAntigens, CD20Biomarkers, TumorCell Line, TumorChemokine CXCL12FemaleHumansImmunohistochemistryMaleMiddle AgedNeoplastic Stem CellsReceptors, CXCRSignal TransductionSyndecan-1Tumor MicroenvironmentUp-RegulationACKR3 protein, humanAntigens, CD20Biomarkers, TumorChemokine CXCL12CXCL12 protein, humanReceptors, CXCRSDC1 protein, humanSyndecan-1

Identifiers

PMID26878134
OpenAlexW2273629980

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.